16 May 2022
Maxwellia appoints Ian Adamson as Strategic Advisor
Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a...
28 April 2022
Catapult Ventures records 3.3x return from exit of Panthera Biopartners
28 April 2022 - Manchester, UK. The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding package for Panthera from Business...
26 April 2022
Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline
MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral contraceptive brands to be available in pharmacy. It...
13 April 2022
Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target … OXFORD, England and SAN JOSE, Calif., April 13, 2022 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a clinical...
11 April 2022
OBT to present preliminary clinical data from ongoing Expansion Phase I Trial
• Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable tolerability profile; recommended dose was defined at 3.0 mg/kg … • OBT076 showed preliminary signs of clinical activity as...
7 April 2022
Proveca announces agreement with Biopas Laboratories
Proveca Ltd is excited to announce a significant agreement outside Europe with Biopas Laboratories based in Colombia. Biopas will commercialise and distribute Sialanar® exclusively throughout Spanish speaking territories in South America. Under the terms of the agreement...
5 April 2022
Cell Guidance Systems and Manchester BIOGEL Collaborate to Launch PODS-PeptiGels for 3D Cell Culture
CAMBRIDGE & MANCHESTER, England- Cell Guidance Systems Ltd, a specialist in the control, manipulation, and monitoring of cells, both in vitro and in vivo, and Manchester BIOGEL, a biotechnology company specialising in the design and manufacture of 3D synthetic peptide...
31 March 2022
Pill Connect releases adherence data to demonstrate efficacy of smart dosing technology
Pill Connect, the smart dosing technology provider, has today announced the availability of patient adherence data to support the launch of its Smart Dispenser technology. Adherence levels in clinical trials have long been a key challenge for pharma partners, with 30-50% of...
24 March 2022
Blueberry Therapeutics provides R&D update and reports progress across dermatology portfolio
• Phase 2 trial with BB2603 in onychomycosis: continues, with initial readout expected in Q1 2023 … • Phase 3 trial with BB1202 for tinea pedis: ready to enter late-stage clinical development with Blueberry seeking advice from regulatory agency to finalise trial design … • Phase...
23 March 2022
You & Type 2 diabetes project helps transform patient experiences supported by Healum technology
A project focused on delivering personalised care for people living with Type 2 diabetes has recently been carried out across South West London. You & Type 2 was designed to make it easier for people with Type 2 diabetes to get the most from health and social care systems.